Q2 2026 saw stable EBITDA and revenue growth, with strong segment volumes but higher costs and a NOK 337 million Alginor impairment. Guidance was revised for BioSolutions and BioMaterials, and a NOK 150 million cost savings program was launched.Based on Borregaard ASA [BRG] Q2 2026 Audio Transcript…
Q2 2026 saw stable EBITDA and revenue growth, with strong segment volumes but higher costs and a NOK 337 million Alginor impairment. Guidance was revised for BioSolutions and BioMaterials, and a NOK 150 million cost savings program was launched.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
